Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ipomea pes-caprae ointment is an investigational botanical drug product developed by Mahidol University for the treatment of jellyfish dermatitis. The active ingredient is an extract derived from *Ipomoea pes-caprae* (beach morning glory), a plant traditionally used in Thai medicine for its anti-pruritogenic and anti-inflammatory properties. The extract contains a variety of bioactive phytochemicals, including isochlorogenic acid A, E-phytol, and β-damascenone. Its mechanism of action involves antispasmodic activity that inhibits vascular smooth muscle contractions and anti-inflammatory effects that neutralize the toxic components of jellyfish venom. The ointment is being evaluated as an add-on therapy to standard care to reduce healing time and alleviate symptoms of jellyfish stings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ipomea pes-caprae ointment.